gms | German Medical Science

29. Kongress der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation, Interventionelle und Refraktive Chirurgie (DGII)

Gesellschaft für Intraokularlinsen-Implantation, Interventionelle und Refraktive Chirurgie (DGII)

26. - 28.02.2015, Karlsruhe

Review of new implants in glaucoma surgery

Meeting Abstract

Suche in Medline nach

  • Keith Barton - London, UK

Deutschsprachige Gesellschaft für Intraokularlinsen-Implantation, Interventionelle und Refraktive Chirurgie. 29. Kongress der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation, Interventionelle und Refraktive Chirurgie (DGII). Karsruhe, 26.-28.02.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. Doc15dgii025

doi: 10.3205/15dgii025, urn:nbn:de:0183-15dgii0250

Veröffentlicht: 25. Februar 2015

© 2015 Barton.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

In the second half of the 20th century there were very few really significant advances in glaucoma surgery. Large pharmaceutical companies dominated glaucoma therapy and continued to promote early diagnosis potentially increasing drug sales. In the last 4 years most glaucoma medications have become generic and there is little likelihood of a new class of glaucoma medications appearing that might compete effectively in the marketplace with generic latanoprost.

While new glaucoma medical therapy innovation is occurring in the drug delivery arena, there has been unprecendented investment in ophthalmic innovation in terms of investment.

A significant proportion of this investment is in new glaucoma devices, fuelled not only by an unmet market need, but also by a dramatic slowing in corneo-refractive innovation eg. failure to cure presbyopia.

New glaucoma surgical devices fall roughly into two camps, those that make an attractive add-on procedure to cataract surgery, potentially helping to reduce the glaucoma medication burden in the longer term. These devices have a theoretical widespread appeal to cataract as well as glaucoma surgeons.

The second camp is the more technically challenging procedure eg. Involving the use of mitomycin C that will more likely appeal to glaucoma specialists and not the overall cataract surgical community.

This talk will review these classes of device, likely new entrants and their relative positioning in the market place.